Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)
- Conditions
- Testicular Neoplasms
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 36
- Registration Number
- NCT06309732
- Locations
- 🇬🇧
Barts and the London NHS Trust, London, United Kingdom
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Procedure: Breast Surgery
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 85
- Registration Number
- NCT06291064
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
- Conditions
- Bladder CancerNon-muscle Invasive Bladder CancerLow-risk
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- University of Bern
- Target Recruit Count
- 28
- Registration Number
- NCT06227065
- Locations
- 🇨🇭
Roland Seiler, Biel, Switzerland
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Disitamab Vedotin Injection （12 weeks）Drug: Disitamab Vedotin Injection （18 weeks）Drug: Sequential CTX
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06227117
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
- Conditions
- Early-stage Breast CancerBreast Cancer InvasiveHER2 Low Breast CarcinomaHormone-receptor-positive Breast Cancer
- Interventions
- Drug: Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 160
- Registration Number
- NCT06144944
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple MyelomaExtramedullary Multiple MyelomaPrimary Plasma Cell Leukemia
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 54
- Registration Number
- NCT06140966
- Locations
- 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- Procedure: Sentinel Lymph Node Biopsy (SLNB)Biological: Tumor-draining lymph node-derived lymphocyte (LNL)Biological: Interleukin-2
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Target Recruit Count
- 24
- Registration Number
- NCT06121570
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1728
- Registration Number
- NCT06112379
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT06107673
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
- Conditions
- Breast CancerNeoadjuvant Therapy
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 181
- Registration Number
- NCT05983094
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.